Lead Small-Molecule Inhibitor

About Eris Biotech

Eris Biotech is a private, preclinical-stage biotech targeting a fundamental challenge in oncology: immune evasion. The company's core asset is a first-in-class, oral small-molecule inhibitor designed to reawaken the immune system against cancer by blocking a specific evasion pathway, distinct from checkpoint inhibitors. This mechanism, which is not dependent on a single protein target, could offer a safer, more convenient treatment option with applicability across a wider range of patients. Backed by undisclosed investors, the company is positioned in the competitive but high-potential field of next-generation immuno-oncology.

Therapeutic Areas

Other Oncology (unspecified) Drugs